Abstract:BACKGROUND:Human-induced pluripotent stem cells (iPSCs) are a potentially unlimited source for generation of cardiomyocytes (iPSC-CMs). However, current protocols for iPSC-CM derivation face several challenges, including variability in somatic cell sources and inconsistencies in cardiac differentiation efficiency. OBJECTIVES:This study aimed to assess the effect of epigenetic memory on differentiation and function of iPSC-CMs generated from somatic cell sources of cardiac versus noncardiac origins. METHODS:Cardiac progenitor cells (CPCs) and skin fibroblasts from the same donors were reprogrammed into iPSCs and differentiated into iPSC-CMs via embryoid body and monolayer-based differentiation protocols. RESULTS:Differentiation efficiency was found to be higher in CPC-derived iPSC-CMs (CPC-iPSC-CMs) than in fibroblast-derived iPSC-CMs (Fib-iPSC-CMs). Gene expression analysis during cardiac differentiation demonstrated up-regulation of cardiac transcription factors in CPC-iPSC-CMs, including NKX2-5, MESP1, ISL1, HAND2, MYOCD, MEF2C, and GATA4. Epigenetic assessment revealed higher methylation in the promoter region of NKX2-5 in Fib-iPSC-CMs compared with CPC-iPSC-CMs. Epigenetic differences were found to dissipate with increased cell passaging, and a battery of in vitro assays revealed no significant differences in their morphological and electrophysiological properties at early passage. Finally, cell delivery into a small animal myocardial infarction model indicated that CPC-iPSC-CMs and Fib-iPSC-CMs possess comparable therapeutic capabilities in improving functional recovery in vivo. CONCLUSIONS:This is the first study to compare differentiation of iPSC-CMs from human CPCs versus human fibroblasts from the same donors. The authors demonstrate that although epigenetic memory improves differentiation efficiency of cardiac versus noncardiac somatic cell sources in vitro, it does not contribute to improved functional outcome in vivo.

Differentiation And Application Of Human Pluripotent Stem Cells Derived Cardiovascular Cells For Treatment Of Heart Diseases: Promises And Challenges

Comments about Possible Use of Human Embryonic Stem Cell-Derived Cardiomyocytes to Direct Autologous Adult Stem Cells into the Cardiomyogenic Lineage

Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy

Human Induced Pluripotent Stem Cell for Modeling Cardiovascular Diseases.

Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells.

Generation, expansion, and differentiation of cardiovascular progenitor cells from human pluripotent stem cells.

Human Pluripotent Stem Cell-Derived Cardiovascular Cells: From Developmental Biology to Therapeutic Applications

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies

Human pluripotent stem cell-based models of heart development and disease

Induced pluripotent stem cells and cardiovascular disease

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Advances in the differentiation of pluripotent stem cells into vascular cells

Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy

Concise Review: Optimized Strategies for Stem Cell-based Therapy in Myocardial Repair: Clinical Translatability and Potential Limitation.

Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications

Induced pluripotent stem cells for cardiovascular therapeutics: Progress and perspectives

Progress of Differentiating Human Embryonic Stem Cells into Endothelial Progenitor Cells and Potential Applications

Cardiac Cell Therapy with Pluripotent Stem Cell-Derived Cardiomyocytes: What Has Been Done and What Remains to Do?

Application of Pluripotent Stem Cells in Cardiac Development and Disease Research

Scalable Cardiac Differentiation of Pluripotent Stem Cells Using Specific Growth Factors and Small Molecules